The Phase IIb POWER 1 and 2 trials compared the efficacy and safety of darunavir plus low-dose ritonavir (darunavir/ritonavir) with currently available PIs in highly treatment-experienced patients ...

The third pivotal study in treatment-naive patients compared dolutegravir to the DHHS guideline recommended boosted protease inhibitor darunavir/ritonavir. The FLAMINGO study is a 96-week ...

The majority (83%) received protease inhibitors in combination with tenofovir; specifically, 74% received ritonavir-boosted protease inhibition. Didanosine was the most commonly (43%) prescribed ...

Some patients taking an extended course of nirmatrelvir/ritonavir outside the context of an acute infection experienced a meaningful reduction in symptoms, but not all benefits persisted. Alison K.

Meaningful reduction in symptoms was seen for some taking an extended course outside of the context of an acute infection. HealthDay News — Extended-course nirmatrelvir/ritonavir yields a meaningful ...

A 52-year-old, HIV-positive man presents with penile lesions that have persisted despite treatment with acyclovir. A 52-year-old, HIV-positive man presents with a ...

ritonavir (Norvir) can increase the risk of side effects from Xhance clarithromycin — can increase the risk of side effects from Xhance nefazodone — can increase the risk of side effects from ...

An estimated 1.2 million people in the U.S. are living with human immunodeficiency virus (HIV). 1 Since the introduction of antiretroviral therapy (ART) almost three decades ago, life expectancy has ...